191 related articles for article (PubMed ID: 10613656)
1. The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation--a comparison with other anticoagulants.
Mohri M; Sugimoto E; Sata M; Asano T
Thromb Haemost; 1999 Dec; 82(6):1687-93. PubMed ID: 10613656
[TBL] [Abstract][Full Text] [Related]
2. Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates.
Tanaka KA; Fernández JA; Marzec UM; Kelly AB; Mohri M; Griffin JH; Hanson SR; Gruber A
Br J Haematol; 2006 Jan; 132(2):197-203. PubMed ID: 16398653
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant human soluble thrombomodulin (rhs-TM) on clot-induced coagulation in human plasma.
Mohri M; Suzuki M; Sugimoto E; Sata M; Yamamoto S; Maruyama I
Thromb Haemost; 1998 Dec; 80(6):925-9. PubMed ID: 9869162
[TBL] [Abstract][Full Text] [Related]
4. The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation.
Tanaka KA; Szlam F; Levy JH
Br J Haematol; 2006 Jul; 134(1):77-82. PubMed ID: 16803571
[TBL] [Abstract][Full Text] [Related]
5. In vitro anticoagulant properties of a minimum functional fragment of human thrombomodulin and in vivo demonstration of its benefit as an anticoagulant in extracorporeal circulation using a monkey model.
Suzuki M; Mohri M; Yamamoto S
Thromb Haemost; 1998 Feb; 79(2):417-22. PubMed ID: 9493601
[TBL] [Abstract][Full Text] [Related]
6. Evidence that the protein C activation pathway amplifies the inhibition of thrombin generation by recombinant human thrombomodulin in plasma.
Ohishi R; Watanabe N; Aritomi M; Gomi K; Kiyota T; Yamamoto S; Ishida T; Maruyama I
Thromb Haemost; 1993 Sep; 70(3):423-6. PubMed ID: 8259542
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637.
Deinum J; Mattsson C; Inghardt T; Elg M
Thromb Haemost; 2009 Jun; 101(6):1051-9. PubMed ID: 19492147
[TBL] [Abstract][Full Text] [Related]
8. Potential value of human thrombomodulin and DAF expression for coagulation control in pig-to-human xenotransplantation.
Miwa Y; Yamamoto K; Onishi A; Iwamoto M; Yazaki S; Haneda M; Iwasaki K; Liu D; Ogawa H; Nagasaka T; Uchida K; Nakao A; Kadomatsu K; Kobayashi T
Xenotransplantation; 2010; 17(1):26-37. PubMed ID: 20149186
[TBL] [Abstract][Full Text] [Related]
9. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
Colucci M; Simioni P; Piro D; Prandoni P; Pagnan A; Semeraro N
Haematologica; 2003 Dec; 88(12):1383-9. PubMed ID: 14687992
[TBL] [Abstract][Full Text] [Related]
10. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma.
Lindhout T; Blezer R; Hemker HC
Thromb Haemost; 1990 Nov; 64(3):464-8. PubMed ID: 2096492
[TBL] [Abstract][Full Text] [Related]
11. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.
Furugohri T; Sugiyama N; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1076-83. PubMed ID: 22012070
[TBL] [Abstract][Full Text] [Related]
12. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
Carr ME; Angchaisuksiri P; Carr SL; Martin EJ
Cell Biochem Biophys; 2003; 39(2):89-99. PubMed ID: 14515016
[TBL] [Abstract][Full Text] [Related]
13. Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin.
Wang YX; Wu C; Vincelette J; Martin-McNulty B; Alexander S; Larsen B; Light DR; McLean K
Thromb Haemost; 2006 Sep; 96(3):317-24. PubMed ID: 16953273
[TBL] [Abstract][Full Text] [Related]
14. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis).
Mohri M; Gonda Y; Oka M; Aoki Y; Gomi K; Kiyota T; Sugihara T; Yamamoto S; Ishida T; Maruyama I
Blood Coagul Fibrinolysis; 1997 Jul; 8(5):274-83. PubMed ID: 9282791
[TBL] [Abstract][Full Text] [Related]
15. The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution.
De Smedt E; Wagenvoord R; Coen Hemker H
Thromb Haemost; 2009 Jan; 101(1):165-70. PubMed ID: 19132204
[TBL] [Abstract][Full Text] [Related]
16. The efficiency of anti-activated factor X and anti-activated factor II anticoagulants.
Stief TW
Blood Coagul Fibrinolysis; 2007 Apr; 18(3):265-9. PubMed ID: 17413764
[TBL] [Abstract][Full Text] [Related]
17. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B.
Hosaka Y; Takahashi Y; Ishii H
Thromb Haemost; 1998 Feb; 79(2):371-7. PubMed ID: 9493593
[TBL] [Abstract][Full Text] [Related]
18. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of factor IIa inhibitors on the endogenous thrombin potential.
Beilfuss A; Grandoch M; Wenzel F; Hohlfeld T; Schrör K; Weber AA
Ther Drug Monit; 2008 Dec; 30(6):740-3. PubMed ID: 18824953
[TBL] [Abstract][Full Text] [Related]
20. Enhancing protein C interaction with thrombin results in a clot-activated anticoagulant.
Richardson MA; Gerlitz B; Grinnell BW
Nature; 1992 Nov; 360(6401):261-4. PubMed ID: 1436107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
